Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare technology company focused on revolutionizing prescription access and distribution, announced significant Q2 2025 operational results. The company has expanded its platform with 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and more than 275 pharmacies added to its national network. This growth is part of Wellgistics' strategy to create a modern drug ecosystem that connects manufacturers directly to pharmacies, providers, employers, and patients. The platform aims to streamline fulfillment, reduce costs, and bypass legacy bottlenecks through a fully integrated, AI-powered infrastructure. As Wellgistics advances toward direct-to-patient care programs, it plans to leverage its expanding distribution, fulfillment, and pharmacy network to support new models of care, aligning pharmaceutical manufacturers with a streamlined path to market while offering patients faster, more transparent prescription access.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。